Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062439 · ClinicalTrials.gov registry record · Phase 2
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT00062439 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 46 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00062439, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining cisplatin and etoposide with radiation therapy may shrink the tumor so it can be removed by surgery. Giving docetaxel after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well giving chemoradiotherapy together with cisplatin and etoposide followed by surgery and docetaxel works in treating patients with newly diagnosed Pancoast tumors, a type of non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG etoposide
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas, PA - Kingman - Kingman
- Southwest Medical Center - Liberal
- Cancer Center of Kansas, PA - Newton - Newton
- Cancer Center of Kansas, PA - Parsons - Parsons
- Cancer Center of Kansas, PA - Pratt - Pratt
- Cancer Center of Kansas, PA - Salina - Salina
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
- Regional Cancer Center at Memorial Medical Center - Springfield
- Carle Cancer Center at Carle Foundation Hospital - Urbana
- CCOP - Carle Cancer Center - Urbana
Alabama
- Mobile Infirmary Medical Center - Mobile
Colorado
- Poudre Valley Hospital - Fort Collins
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Indiana
- Saint Anthony Memorial Health Centers - Michigan City
Iowa
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062439
The ClinicalTrials.gov registry entry for NCT00062439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00062439 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Kansas, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT00062439 about?
NCT00062439 is a clinical study titled "S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors". RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining cisplatin and etoposide with radiation therapy may shrink t...
What is the current status of trial NCT00062439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-07. Estimated completion is 2010-12.
What conditions does trial NCT00062439 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00062439?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), etoposide (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00062439?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062439 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.